Moreover, activated HRAS mutations were detected in nonalcoholic fatty liver disease (NAFLD)–associated HCC in mice (Shen et al., 2016), which is increasingly regarded as a promotor of hepatocarcinogenesis. Here, HRAS is linked to metabolic dysfunction-associated steatotic liver disease.